Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation

TY - JOUR

T1 - Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations

T2 - a systematic review and economic evaluation

AU - Bryant, J.

AU - Cooper, K.

AU - Picot, J.

AU - Clegg, A.

AU - Roderick, P.

AU - Rosenberg, W.

AU - Patch, C.

PY - 2009/4

Y1 - 2009/4

N2 - Objective: To evaluate DNA testing for detecting hereditary haemochromatosis (HHC) in subgroups of patients suspected of having the disorder and in family members of those diagnosed with HHC.Data sources: Major electronic databases, searched from inception to April 2007.Review methods: A systematic review was undertaken using a priori methods and a de novo model developed to assess costs and consequences of DNA testing.Results: Eleven studies were identified for estimating the clinical validity of genotyping for the C282Y mutation for the diagnosis of HHC. No clinical effectiveness studies meeting the inclusion criteria were identified. Two North American cost-effectiveness studies of reasonable quality were identified but their generalisability to the UK is not clear. Three cohort studies met the inclusion criteria for the review of psychosocial aspects. All had methodological limitations and their generalisability is difficult to determine. The clinical sensitivity of C282Y homozygosity for HHC ranged from 28.4% to 100%, or from 91.3% to 92.4% when considering only the most relevant studies. Clinical specificity ranged from 98.8% to 100%. One study found that gene testing was a cost-effective method of screening relatives of patients with haemochromatosis, whereas the other found that genotyping the spouse of a homozygote was the most cost-efficient strategy. Genetic testing for haemochromatosis appears to be well accepted, is accompanied by few negative psychosocial outcomes and may lead to reduced anxiety. The de novo economic model showed that, in people suspected of having haemochromatosis, the DNA strategy is cost saving compared with the baseline strategy using liver biopsy (cost saved per case detected 123) pound, largely because of the reduction in liver biopsies. For family testing of siblings the DNA strategy is not cost saving because of the costs of the DNA test (additional cost per case detected 200) pound. If the cost of the test were to reduce from 100 pound to 60 pound, the DNA strategy would be the cheaper one. For family testing of offspring the DNA test strategy is cheaper than the baseline biochemical testing strategy (cost saved per case detected 7982) pound. Sensitivity analyses showed that the conclusions in each case are robust across all reasonable parameter values.Conclusions: The preferred strategy in practice is DNA testing in conjunction with testing iron parameters when there is clear clinical indication of risk for haemochromatosis because of biochemical criteria or when there is familial risk for HHC. Access to genetic testing and centralisation of test provision in expert laboratories would lower the cost of testing, improve the cost-effectiveness of the strategy and improve the quality of information provided to clinicians and patients.

AB - Objective: To evaluate DNA testing for detecting hereditary haemochromatosis (HHC) in subgroups of patients suspected of having the disorder and in family members of those diagnosed with HHC.Data sources: Major electronic databases, searched from inception to April 2007.Review methods: A systematic review was undertaken using a priori methods and a de novo model developed to assess costs and consequences of DNA testing.Results: Eleven studies were identified for estimating the clinical validity of genotyping for the C282Y mutation for the diagnosis of HHC. No clinical effectiveness studies meeting the inclusion criteria were identified. Two North American cost-effectiveness studies of reasonable quality were identified but their generalisability to the UK is not clear. Three cohort studies met the inclusion criteria for the review of psychosocial aspects. All had methodological limitations and their generalisability is difficult to determine. The clinical sensitivity of C282Y homozygosity for HHC ranged from 28.4% to 100%, or from 91.3% to 92.4% when considering only the most relevant studies. Clinical specificity ranged from 98.8% to 100%. One study found that gene testing was a cost-effective method of screening relatives of patients with haemochromatosis, whereas the other found that genotyping the spouse of a homozygote was the most cost-efficient strategy. Genetic testing for haemochromatosis appears to be well accepted, is accompanied by few negative psychosocial outcomes and may lead to reduced anxiety. The de novo economic model showed that, in people suspected of having haemochromatosis, the DNA strategy is cost saving compared with the baseline strategy using liver biopsy (cost saved per case detected 123) pound, largely because of the reduction in liver biopsies. For family testing of siblings the DNA strategy is not cost saving because of the costs of the DNA test (additional cost per case detected 200) pound. If the cost of the test were to reduce from 100 pound to 60 pound, the DNA strategy would be the cheaper one. For family testing of offspring the DNA test strategy is cheaper than the baseline biochemical testing strategy (cost saved per case detected 7982) pound. Sensitivity analyses showed that the conclusions in each case are robust across all reasonable parameter values.Conclusions: The preferred strategy in practice is DNA testing in conjunction with testing iron parameters when there is clear clinical indication of risk for haemochromatosis because of biochemical criteria or when there is familial risk for HHC. Access to genetic testing and centralisation of test provision in expert laboratories would lower the cost of testing, improve the cost-effectiveness of the strategy and improve the quality of information provided to clinicians and patients.

KW - PERCUTANEOUS LIVER-BIOPSY

KW - LONG-TERM SURVIVAL

KW - TRANSFERRIN SATURATION VALUES

KW - SERUM FERRITIN CONCENTRATIONS

KW - DECISION-ANALYSIS MODEL

KW - VOLUNTARY BLOOD-DONORS

KW - 2 SCREENING STRATEGIES

KW - HFE C282Y HOMOZYGOTES

KW - IRON-BINDING-CAPACITY

KW - QUALITY-OF-LIFE

M3 - Literature review

SN - 1366-5278

VL - 13

SP - 1-+

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 23

ER -